Samsung Biologics inks 2 new deals worth 668 mn with European pharma By IANS - Investing.com India

207940 Stock   934,000  2,000  0.21%   
About 55% of Samsung Biologics' investor base is interested to short. The analysis of current outlook of investing in Samsung Biologics Co suggests that many traders are impartial regarding Samsung Biologics' prospects. The current market sentiment, together with Samsung Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Samsung Biologics stock news signals to limit their universe of possible portfolio assets.
  
Samsung Biologics inks 2 new deals worth 668 mn with European pharma By IANS Investing.com India

Read at news.google.com
Google News at Macroaxis
  

Samsung Biologics Fundamental Analysis

We analyze Samsung Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Samsung Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Samsung Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Samsung Biologics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Samsung Biologics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Samsung Biologics stock to make a market-neutral strategy. Peer analysis of Samsung Biologics could also be used in its relative valuation, which is a method of valuing Samsung Biologics by comparing valuation metrics with similar companies.

Complementary Tools for Samsung Stock analysis

When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals